- Previous Close
0.6604 - Open
0.7419 - Bid 0.5381 x 200
- Ask 0.9109 x 200
- Day's Range
0.6940 - 0.7800 - 52 Week Range
0.6410 - 3.1000 - Volume
1,534,248 - Avg. Volume
380,103 - Market Cap (intraday)
10.678M - Beta (5Y Monthly) 1.11
- PE Ratio (TTM)
-- - EPS (TTM)
-1.6100 - Earnings Date Mar 13, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.50
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
indaptusrx.comRecent News: INDP
View More
Performance Overview: INDP
Trailing total returns as of 3/25/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: INDP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: INDP
View MoreValuation Measures
Market Cap
9.53M
Enterprise Value
3.83M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.42
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-86.27%
Return on Equity (ttm)
-187.52%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-15.02M
Diluted EPS (ttm)
-1.6100
Balance Sheet and Cash Flow
Total Cash (mrq)
5.79M
Total Debt/Equity (mrq)
2.13%
Levered Free Cash Flow (ttm)
-6.86M
Research Analysis: INDP
View MoreCompany Insights: INDP
INDP does not have Company Insights